NEW YORK (GenomeWeb) – Vermillion and Moffitt Cancer Center said yesterday that they are collaborating on a study aimed at generating clinical and economic data to support the use of molecular diagnostics, including Vermillion's OVA1 test, in ovarian cancer care.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.